400-650-8846

全国客服热线(7*24小时)

首页 > 品牌直通
旗下分类
Svar
Svar
Svar 公司专注于大分子配体结合分析和基于细胞的分析研究,在抗体和多肽药物、基因和载体的治疗方面丰富有经验,涉及领域包括 肿瘤学、自身免疫、内分泌疾病和神经学相关研究领域,同时提供相关领域疾病的药物和解决方案,提供完整的CRO 产品。
  • 品牌详情
  • 旗下新品
Svar 公司专注于大分子配体结合分析和基于细胞的分析研究,在抗体和多肽药物、基因和载体的治疗方面丰富有经验,涉及领域包括肿瘤学、自身免疫、内分泌疾病和神经学相关研究领域,同时提供相关领域疾病的药物和解决方案,提供完整的CRO 产品。
北京博蕾德生物是Svar 公司授权的中国区总代理,更多Svar 公司产品信息,请咨询北京博蕾德生物科技有限公司。
以下是Svar 公司授权博蕾德生物为中国区总代理授权书。

特色产品推荐:
**补体检测试剂盒

1)药物开发-补体靶向治疗
研究表明,炎性疾病的发生、发展同补体的活化有关。因此,如何干扰和抑制补体活化产生的有害作用,成为药理学研究的焦点之一,Euro Diagnostica试剂盒用于评估补体靶向治疗效果(参考文献4-8)。
2)临床研究-补体功能/活性监测
补体功能的评估在补体相关疾病的发生和治疗中具有重要意义。文献5-9 用Euro Diagnostica试剂盒监测补体疾病治疗中补体水平。
3)补体脱靶反应
在某些情况下,补体激活可引起严重反应,比如候选药物的脱靶反应,抗体依赖的补体激活,移植排斥反应。((参考文献12-13)。)
订购信息
货号 产品名称 规格
COMPL300 Complement system Screen WIESLAB® 96T
COMPLCP310 Complement system Classical Pathway WIESLAB® 96T
COMPLMP320 Complement system MBL pathway WIESLAB® 96T
COMPLAP330 Complement system Alternative Pathway WIESLAB® 96T
应用文献:
1.Ricklin D and Lambris JD.Complement in Immune and Inflammatory Disorders:Therapeutic Interventions. J Immunol 2013; 190: 3839-3847
2. Seelen MA et al. Functional analysis of the classical, alternative, and MBL pathways of
the complement system: standardization and validation of a simple ELISA. J Immunol Meth 2005; 296: 187–198
3. Salvesen B and Mollnes TE. Pathway-specific complement activity in pigs evaluated with a human functional complement assay. Mol Imm 2009;6:1620-1625
4.Hill A et al. A Subcutaneously Administered Investigational RNAi Therapeutic (ALN-CC5) Targeting Complement C5 for Treatment of PNH and Complement-Mediated Diseases: Interim Phase 1 Study Results. Abstract 2413 ;58th ASH Annual Meeting 2015
5. Jore MM et al. Structural basis for therapeutic inhibition of complement C5. Nature Structural & Molecular Biology 2016: doi:10.1038/nsmb.3196
6. Würzner R et al. Assessment of complement activity by ELISA. Abstract #41 16th Biennial Meeting of the European Society for Immunodeficiencies, ESID 2014
7. Kocsis A. Selective Inhibition of the Lectin Pathway of Complement with
Phage Display Selected Peptides against Mannose-Binding Lectin-Associated Serine
Protease (MASP)-1 and -2: Significant Contribution of MASP-1 to Lectin Pathway
Activation. J of Immunol 2010;185: 4169–4178
8. Kadam A P and Sahu A Identification of Complin, a Novel Complement Inhibitor that Targets Complement Proteins Factor B and C2. J of Immunol 2010;184: 7116-24
9. Volokhina E B et al. Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndrome. Clin Immunol 2015; 160: 237–43
10. Heinen S et al. Monitoring and modeling treatment of atypical hemolytic uremic
syndrome. Molecular Immunology 2013; 54:84– 88
11. Hallenstensen RF et al. Eculizumab treatment during pregnancy does not affect the
complement system activity of the newborn. Immunobiology 2015; 220:452–459
12. Castellano G et al. Therapeutic Targeting of Classical and Lectin Pathways of Complement Protects from Ischemia-Reperfusion- Induced Renal Damage. Am J Pathol 2010; 176:1648–1659
13. Brennan FR et al. Safety and immunotoxicity assessment of immunomodulatory
monoclonal antibodies. mAbs 2010; 2:3, 233-255
14. Mitsuru Sugimoto,etal.Possible participation of IgG4 in the activation of complement in IgG4-related disease with  hypocomplementemia.Modern Rheumatology,Volume 26, 2016 - Issue 2
15.Y. Palarasah,etal.Novel assays to assess the functional capacity of the classical, the alternative and the lectin pathways of the complement system.Clincal&Experimental Immunology,Volume164, Issue3,June 2011,Pages 388-395.
 


 

上一篇:Diazyme

下一篇:返回列表

品牌 货号 产品名称 规格 货期 单价 操作